Evidence map›Paper›PMID 41746062›Full record

ReviewVaccines2026

New HPV Vaccines on the Market and Future Trends: A State-of-the-Art Review.

Utku Akgör, Bilal Esat Temiz, Murat Cengiz, Hasan Volkan Ege, Elmar Joura, Murat Gültekin

Abstract readReview
In one paragraph

Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Utku AkgörFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0003-1377-2651
Bilal Esat TemizFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0002-4329-1376
Murat CengizFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0002-0477-3700
Hasan Volkan EgeDepartment of Gynecologic Oncology, Etlik City Hospital, 06010 Ankara, Türkiye.ORCID 0000-0002-4056-9037
Elmar JouraDepartment of Gynecology and Obstetrics, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0003-0885-1013
Murat GültekinFaculty of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University, 06230 Ankara, Türkiye.ORCID 0000-0002-4221-4459

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Next-generation human papillomavirus (HPV) vaccines encompass newly licensed and emerging formulations that employ alternative production platforms, expanded valency, or novel antigenic targets beyond conventional L1-based vaccines. These vaccines aim to address affordability challenges, supply limitations, and suboptimal vaccination coverage, particularly in low- and middle-income countries. This review aggregates current clinical, immunological, and programme-related evidence on newly licensed vaccines, including the World Health Organization (WHO)-prequalified bivalent formulations (Cecolin

Indexed as

HPV vaccineshuman papillomavirusimmunogenicityL2-based vaccine candidatesnext-generation HPV vaccines

Identifiers

PMID41746062
PMCPMC12944895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.